active
Early Investigator Research Award
Offered by Department of Defense (USA)
<p>Decrease the clinical impact of neurofibromatosis Neurofibromatosis (NF) is a group of three genetically distinct disorders that cause tumors to grow in the nervous system. It also produces other abnormalities in the skin and bones. There are three types of NF: 1) Neurofibromatosis Type 1 or NF1 affects 1 in 3500 people worldwide and is caused by a mutation in the neurofibromin gene, 2) Neurofibromatosis Type 2 or NF2 affects 1 in 25,000 people and is caused by mutations in the Merlin gene, 3) Schwannomatosis is much rarer, affecting 1 in 40,000 people, and although mutations in the SMARCB1/INI1 gene have been associated with the disease, we do not fully understand the underlying cause to many of the symptoms of the disorder.</p> <p>The Neurofibromatosis Research Program (NFRP) was established in 1996 when the efforts of NF advocates led to a congressional appropriation to fund research in NF. <span style="text-decoration: underline;">The investigator must:</span> <strong>Be involved in a postdoctoral training or medical residency program; Possess up to 4 years of continuous postdoctoral research experience by application submission deadline; and Possess a doctoral degree (i.e., Ph.D., M.D./Ph.D., D.O./Ph.D.) or a clinical doctoral degree (i.e., M.D./D.O. or Ph.D. in a clinical discipline) from an accredited organization or program. Must commit at least 50% of effort to the project.</strong></p>
Key Details
Deadline Thursday, 21 July 2022
Eligible Applicant Country Worldwide
Host Country Any except Cuba and Iran
Years Since PhD 4
Mobility Rule No
Research Costs Covered $200,000
Career Levels
Fields
Molecular biology, clinical genetics, translational medicine
Record Information
Last Verified 19 February 2026 by asntech
Added June 2022
Last Updated June 2022
Source legacy-import